Clarus Therapeutics Holdings, Inc.
DelistedCIK 1817944fmd_11SNH82AX3JH77G13FXXGEVXC2Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Jun 30, 2022, 10 periods
| Line item | FY2020 | FY2021 |
|---|---|---|
| Total revenues | 6 | 14 |
| Cost of revenue | 9 | 3 |
| Gross profit | (2) | 11 |
| Research and development | 2 | 4 |
| Total operating expenses | 45 | 51 |
| Operating income | (47) | (40) |
| Interest expense | 15 | 16 |
| Interest and investment income | 0 | 0 |
| Other non-operating income (expense) | 52 | (1) |
| Income before taxes | 4 | (41) |
| Income tax expense | 0 | 0 |
| Net income from continuing operations | (47) | (40) |
| Net income | 4 | (41) |
| Net income to common shareholders | (10) | (40) |